Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.431
AS - Asia 9.317
EU - Europa 7.009
SA - Sud America 1.433
AF - Africa 260
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 18
Totale 31.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.090
SG - Singapore 3.101
CN - Cina 1.983
IT - Italia 1.810
VN - Vietnam 1.692
HK - Hong Kong 1.078
BR - Brasile 1.077
DE - Germania 1.015
RU - Federazione Russa 990
IE - Irlanda 654
SE - Svezia 627
GB - Regno Unito 382
FR - Francia 352
UA - Ucraina 316
IN - India 301
CA - Canada 212
FI - Finlandia 181
PL - Polonia 162
KR - Corea 155
BD - Bangladesh 152
AR - Argentina 145
ID - Indonesia 136
ES - Italia 123
TR - Turchia 122
IQ - Iraq 93
JP - Giappone 90
NL - Olanda 88
ZA - Sudafrica 86
PK - Pakistan 79
MX - Messico 74
BE - Belgio 70
CH - Svizzera 57
EC - Ecuador 46
AT - Austria 45
MA - Marocco 45
UZ - Uzbekistan 44
SA - Arabia Saudita 42
PH - Filippine 41
CO - Colombia 39
DK - Danimarca 36
VE - Venezuela 34
CL - Cile 29
KE - Kenya 28
LT - Lituania 26
TN - Tunisia 26
PE - Perù 24
PY - Paraguay 23
AU - Australia 22
NP - Nepal 19
ET - Etiopia 18
EG - Egitto 17
JO - Giordania 17
TW - Taiwan 17
IR - Iran 16
AE - Emirati Arabi Uniti 14
AZ - Azerbaigian 14
EU - Europa 14
MY - Malesia 14
TH - Thailandia 14
CR - Costa Rica 10
OM - Oman 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
PS - Palestinian Territory 9
DO - Repubblica Dominicana 8
KZ - Kazakistan 8
RO - Romania 8
MU - Mauritius 7
AL - Albania 6
AO - Angola 6
GE - Georgia 6
HN - Honduras 6
IL - Israele 6
KG - Kirghizistan 6
NI - Nicaragua 6
NO - Norvegia 6
PA - Panama 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
GR - Grecia 5
MD - Moldavia 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
BH - Bahrain 4
JM - Giamaica 4
LB - Libano 4
MK - Macedonia 4
MO - Macao, regione amministrativa speciale della Cina 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
AM - Armenia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
LY - Libia 3
PT - Portogallo 3
Totale 31.445
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Singapore 1.728
Ashburn 1.404
Hong Kong 1.044
San Jose 845
Woodbridge 726
Milan 707
Fairfield 689
Frankfurt am Main 657
Dublin 640
Chandler 602
Ho Chi Minh City 516
Houston 451
Wilmington 445
Hanoi 434
New York 378
Dallas 373
Los Angeles 319
Beijing 295
Jacksonville 268
Seattle 265
Hefei 263
Santa Clara 255
Cambridge 247
Dearborn 247
The Dalles 223
Chicago 211
Princeton 172
Seoul 139
Shanghai 132
Lauterbourg 128
Nanjing 125
São Paulo 122
Buffalo 103
Munich 101
Council Bluffs 97
Moscow 94
Jakarta 93
Altamura 83
Lawrence 79
Da Nang 78
Helsinki 78
Tokyo 75
Warsaw 72
Lodz 70
Haiphong 62
Brussels 61
Orem 57
London 52
Johannesburg 51
Guangzhou 49
San Diego 49
Rio de Janeiro 47
Toronto 47
Nuremberg 45
Lachine 44
Boardman 43
Zurich 43
Chennai 42
Montreal 42
Kent 41
Denver 40
Hải Dương 40
Phoenix 40
Poplar 40
Turku 40
Atlanta 39
Fremont 39
Rome 39
Baghdad 36
Brooklyn 36
Lissone 36
Shenyang 36
Stockholm 36
Tashkent 36
Nanchang 33
Desio 32
Andover 31
Amsterdam 30
Biên Hòa 30
Changsha 29
Ottawa 29
Romola 29
Lahore 28
Pune 28
Ankara 27
Boston 27
Göttingen 27
Jinan 27
Salt Lake City 27
Seveso 26
Ha Long 25
Monza 25
Paris 25
Tianjin 25
Dhaka 24
Manchester 24
Buenos Aires 23
Curitiba 23
Nairobi 23
Totale 19.997
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 519
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 443
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 439
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 435
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 421
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 415
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 405
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 391
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 390
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 385
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 373
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 373
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 368
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 361
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 361
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 359
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 357
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 347
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 340
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 330
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 329
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 327
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 326
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 326
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 325
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 324
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 324
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 323
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 322
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 319
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 319
Inhibition of RET tyrosine kinase by SU5416 316
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 308
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 304
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 304
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 304
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 302
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 301
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 301
Dual kinase targeting in leukemia 298
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 296
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 296
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 291
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 287
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 286
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 283
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 278
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 278
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 276
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 276
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 275
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 274
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 273
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 267
We shall overcome (drug resistance) some day 265
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 262
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 259
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 258
Expression, purification, and inhibition of human RET tyrosine kinase 258
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 253
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 251
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 249
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 248
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 245
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 245
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 243
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 243
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 241
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 237
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 234
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 230
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 230
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 229
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 226
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 226
Novel targeted therapeutics for MEN2 225
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 220
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 217
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 217
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 214
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 213
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 212
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 212
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 210
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 210
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 210
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 209
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 207
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 207
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 200
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 198
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 198
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 198
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 198
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 197
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 197
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 192
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 191
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR 188
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 188
Totale 28.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.102
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.102
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021529 0 0 0 0 0 0 0 0 0 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20255.508 275 476 319 278 440 200 369 193 548 880 492 1.038
2025/202613.259 1.935 1.030 1.206 1.673 1.644 753 2.020 617 1.126 1.255 0 0
Totale 32.219